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A B S T R A C T
Objectives: This study sought to identify the incidence of, and risk factors for, acute kidney injury (AKI) in
adults treated with parenteral aciclovir.
Methods: A single-centre retrospective cohort study of prospectively acquired electronic clinical,
pharmacy and laboratory data was performed with approval of the Caldicott guardian. AKI was defined by
Kidney Disease Improving Global Outcomes (KDIGO) criteria, prior to analysis of baseline patient and
treatment-related risk factors.
Results: 269 aciclovir treatment episodes were identified in 268 patients. Overall incidence of AKI was
13%. Half of AKI episodes were KDIGO grade 2/3. In univariate analysis, AKI occurred more frequently in
patients with pre-existing chronic kidney disease (CKD), diabetes, and in patients treated with higher
daily doses of aciclovir. There was also a trend to increased age in patients with AKI. In a binomial logistic
regression model only CKD and daily dose remained significant independent factors.
Conclusions: AKI is an important side effect of parenteral aciclovir, the incidence of which is comparable
to established nephrotoxic drugs such as aminoglycosides. Patients with pre-existing chronic kidney
disease or receiving higher total doses are at greatest risk, reinforcing the clinical importance of
appropriate dose adjustment for ideal body weight and baseline renal function.
© 2018 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Despite well-established links between parenteral aciclovir and
acute kidney injury (AKI) (Brigden et al., 1982; Sawyer et al., 1988;
Rao et al., 2015; Pierson-Marchandise et al., 2017), there are no
population data on risk factors for this complication in adults. The
classic pathomechanism of aciclovir renal toxicity is tubular crystal
deposition, although crystal-independent tubulopathy and acute
tubular necrosis are also reported (Sawyer et al., 1988). We sought
to describe risk factors for AKI in an adult cohort treated with
parenteral aciclovir.* Corresponding author at: 3rd Floor, Leech Building, Medical School, Newcastle
University, Newcastle upon Tyne NE2 4HH, UK.
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1201-9712/© 2018 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Methods
This was a single-centre retrospective cohort study. Caldicott
guardian approval for data collection was granted (Ref: 6189). In
our setting, aciclovir is administered as a slow intravenous infusion
(over at least 60 min) at a concentration of not more than 25 mg/
mL (typically 5 mg/mL). Data on all doses of parenteral aciclovir
administered from 2010 to 2016 to patients in Infectious Diseases,
Neurology and Neurointensive Care departments were extracted
from a prospective electronic pharmacy database. Inclusion
criteria were: age 16 years or above at the time of prescription,
and at least one serum creatinine measurement both at baseline
and within 48 h of the dose. Patients with end-stage renal disease
were excluded. AKI was defined and severity assessed according to
Kidney Disease Improving Global Outcomes (KDIGO) serum
creatinine criteria (Kidney Disease: Improving Global Outcomes
(KDIGO) Acute Kidney Injury Work Group, 2012). Records were
interrogated for a priori defined risk factors. Body-weight wasciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Baseline and disease-related risk factors for AKI in patients treated with aciclovir.
AKI n = 35 (%) No AKI n = 234 (%) P value Odds ratio (95% CI)/
95% CI of difference
Age (range) 57 (20–90) 51 (16–93) 0.084 5.5–6.8
Gender (F/M) 19/16 (54) 112/122 (48) 0.587 1.3 (0.6–2.6)
Chronic kidney disease (Y/N) 5/30 (14) 6/228 (3) 0.007 6.4 (1.8–22.1)
Diabetes (Y/N) 7/28 (20) 18/216 (8) 0.028 3.0 (1.2–7.9)
Heart failure (Y/N) 1/34 (3) 13/221 (6) 0.703 0.5 (0.1–4.0)
Chronic liver disease (Y/N) 2/33 (6) 18/216 (8) 1 0.7 (0.2–3.3)
Cancer (Y/N) 4/31 (11) 21/213 (9) 0.753 1.3 (0.4–4.1)
No comorbidity (Y/N) 23/12 (66) 172/62 (74) 0.417 0.7 (0.3–1.5)
Meningoencephalitis (Y/N) 14/21 (40) 71/163 (30) 0.250 1.5 (0.7–3.2)
Neurointensive care (Y/N) 11/24 (31) 83/151 (35) 0.707 0.8 (0.4–1.8)
Comorbidities were determined based on their presence in prospectively-maintained electronic secondary care records of active clinical problems. Chronic kidney disease
was defined according to KDIGO CKD criteria. No comorbidity refers to the absence of any of the comorbid conditions listed above. Meningoencephalitis is a composite group
of patients treated for meningitis and/or encephalitis. Neurointensive care refers to the setting of aciclovir treatment. Other settings were infectious diseases (n = 117) and
neurology (n = 58), neither of which were associated with AKI. In bold are factors which are significant at P < 0.05 in univariate analysis. 3 AKI patients had concurrent diabetes
and CKD. All factors with P < 0.1 (e.g. age, CKD, diabetes and daily dose, see Table 2) were included in a binomial logistic regression model (Χ2 = 19.2, P < 0.001). Of these, only
CKD (OR 9.5 [95% CI: 2.3–39.3] P = 0.002) and daily dose (see Table 2) remained significant.
98 L. Ryan et al. / International Journal of Infectious Diseases 74 (2018) 97–99retrospectively obtained from case notes of patients with AKI.
Continuous data were normalized by log-transformation for
unpaired t test; categorical data were analysed by Fisher’s exact
test. A binomial logistic regression model was developed for
multivariate analysis. Data were analysed in SPSS (version 24, IBM).
Results
269 aciclovir treatment episodes were identified in 268
patients. Indications for aciclovir therapy were: encephalitis (52/
269, 19%), herpes zoster (49/269, 18%), meningitis (33/269, 12%),
disseminated herpes simplex (10/269, 4%), and other (125/269,
47%). Doses ranged from 5 mg/kg o.d. to 15 mg/kg t.d.s., resulting in
a total daily dose of aciclovir from 235 to 3600 mg.
Thirty-five patients (13% of aciclovir treatment episodes)
developed AKI (grade 1: 19/35 [54%]; grade 2: 6/35 [17%]; grade 3:
10/35 [29%]). No patients required renal replacement therapy. The
median time to AKI was 2 days (range 1–14 days) with 22/35
patients developing AKI within 2 days and 30/35 within 7 days of
the first dose. In response to AKI, aciclovir was either stopped (16/
35), dose-reduced (6/35), switched to oral (2/35) or unchanged
(11/35). Data were available from 19/35 patients to evaluate the
natural history of AKI, which resolved in 4 days (mean, 95% CI: 3–
5), with creatinine returning to baseline within 12 days (mean,
95% CI: 5–19).Table 2
Intervention-related risk factors for AKI in patients treated with aciclovir.
Factor (Y/N) AKI n = 35 (%) No
Any nephrotoxic 26/9 (74) 17
Aminoglycoside 0/35 (0) 10
Beta-lactam 14/21 (40) 85
Glycopeptide 0/35 (0) 2/
Antiviral 0/35 (0) 13
Antifungal 1/34 (3) 9/
Immunosuppressive 1/34 (3) 16
ACE inhibitors 4/31 (11) 21
Diuretics 4/31 (11) 28
Chemotherapy 0/35 (0) 0/
Other nephrotoxics 4/31 (11) 28
Contrast 16/19 (46) 81
Aciclovir dose
Mean daily dose (mg) 2173.7 (1952.7–2394.7) 18
Mean cumulative dose (mg) 7848.2 (4665.6–11030.8) 96
Beta-lactam refers to patients receiving cephalosporins (ceftriaxone, cefotaxime) or penic
at P < 0.05. In a binomial logistic regression model (see Table 1) the only treatment-relate
CI: 1.3–4.5] P = 0.005).Patient and intervention characteristics are summarised in
Tables 1 and 2. Several factors were linked to the development of
AKI, including chronic kidney disease (CKD, defined according to
KDIGO criteria) (OR 6.4, [95% CI: 1.8–22.1] P = 0.007) and diabetes
(OR 3.0, [95% CI: 1.2–7.9] P = 0.028). Patients with AKI also received
a significantly higher daily dose (2174 mg vs 1820 mg, P = 0.004) in
the form of either 5 or 10 mg/kg t.d.s., with the exception of one
patient with CKD who received 5 mg/kg o.d. Documentation of
height in clinical records was insufficient to determine whether
dosing was based on ideal or actual body weight. Only 1/5 patients
with CKD had evidence of appropriate dose-adjustment for renal
function, compared to 4/6 who did not develop AKI. Interestingly,
concomitant administration of nephrotoxic agents (including
radiocontrast) was not a significant risk factor. A binomial logistic
regression model (Χ2 = 19.2, P < 0.001) indicated that daily dose
(OR 2.4 per gram [95% CI: 1.3–4.5] P = 0.005) and CKD (OR 9.5 [95%
CI: 2.3–39.3] P = 0.002) were independent risk factors.
Discussion
The rate of aciclovir-associated AKI reported here is consistent
with previous reports (Brigden et al., 1982; Sawyer et al., 1988; Rao
et al., 2015; Pierson-Marchandise et al., 2017) indicating that in
contemporary clinical practice, aciclovir is comparable to other
more widely-perceived nephrotoxic antimicrobials such as AKI n = 234 (%) P value Odds ratio (95% CI)/
95% CI of difference
3/61 (74) 1 1.0 (0.4–2.2)
/224 (4) 0.370 N/A
/1549 (36) 0.708 1.2 (0.6–2.4)
232 (1) 1 N/A
/221 (6) 0.387 N/A
225 (4) 1 0.7 (0.1–6.0)
/218 (7) 0.488 0.4 (0.1–3.1)
/213 (9) 0.753 1.3 (0.4–4.1)
/206 (12) 1 1.0 (0.3–2.9)
234 (0) 1 N/A
/206 (12) 1 1.0 (0.3–2.9)
/153 (35) 0.258 1.6 (0.8–3.3)
19.9 (1738.4–1901.3) 0.004 111.8–595.9
64.7 (8386.0–10943.3) 0.417 1487.4–2145.5
illins (amoxicillin, piperacillin–tazobactam). In bold are factors which are significant
d factor which remained significant was daily dose (OR 2.4 per gram of aciclovir [95%
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2013). Unlike other antivirals, aciclovir does not compete with
creatinine for tubular excretion (Gunness et al., 2010), therefore
the elevations in serum creatinine we observe are a true reflection
of renal damage. Approximately half of AKI events were grade 2/3,
indicating that aciclovir-associated AKI is clinically relevant.
The central finding of this study is that daily dose and pre-
existing CKD were independent risk factors for AKI, underscoring
the importance of appropriate dose adjustments for ideal body
weight (Seedat and Winnett, 2012) and baseline renal function.
This necessitates measuring creatinine both prior to dosing and
regularly throughout treatment (i.e. daily for at least the first 2–3
days). The main limitation of this retrospective study is that patient
height was not routinely recorded, which is essential for
calculating ideal body weight (IBW), therefore the influence of
overdosing by actual body weight in overweight individuals could
not be determined. Calculating doses based on IBW should
mitigate nephrotoxicity. This will become increasingly relevant
given the growing population prevalence of obesity and in light of
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